Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Нексавар® (сорафениб) в лечении распространенного почечно-клеточного рака
Нексавар® (сорафениб) в лечении распространенного почечно-клеточного рака
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Аксель Е.М., Давыдов М.И. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Вест. РОНЦ им. Н.Н.Блохина РАМН. 2008; 2 (19).
2. Матвеев Б.П., Матвеев В.Б., Волкова М.И. Онкоурология. 2008; 4.
3. Petrilak D et al. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin Am 1993; 29A: 997.
4. Savage PD. Renal cell cancer. Lippincott Co; 1995.
5. Strumberg D et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965–72.
6. Clark JW et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Clin Cancer Res 2005; 11: 5472–80.
7. Awada A et al. Phase I clinical and pharmacokinetic of BAY 43-9006 administered for 21 days on 7 days off in patients with advanced refractory solid tumors. Br J Cancer 2005; 92: 1855–61.
8. Amato R et al. Phase II trail of intra-patient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25: abstr 5026.
9. Szczylik C et al. Randomized phase II trail of first-line treatment with sorafenib vs interferon in patients with advanced renal cell carcinoma. J ClinOncol 2007; 25: abstr 5025.
10. Ryan CW, Goldman BN et al. Sorafenib plus interferon-?2b as first-line therapy for advanced renal cell carcinoma: SWOG 0412. J Clin Oncol 2006; 24: abstr 4525.
11. Gollob J et al. Комбинация сорафениба и интерферона альфа-2b в 1–2 линиях терапии метастатического почечноклеточного рака: исследование II фазы. J Clin Oncol (русское издание). 2007; 1 (4).
12. Ratain MJ, Elsen T et al. Phase II placebo-controlled randomized discontination trail of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–12.
13. Escudier B, Szczylik C et al. Randomized phase III trail of the multikinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Eur J Canc 2005; 3: 226.
14. Escudier B, Eisen T et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 2007; 357: 203.
15. Bukowski R et al. Final results of the randomized phase III trail of sorafenib in advanced renal cell carcinoma. Survival and biomarker analisis. J Clin Oncol 2007; 25: abstr 5023.
16. Knox JJ, Figlin R et al. Inv Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded accsess trail in North America: Safety and efficacy. J Clin Oncol 2007; 25: abstr 5011.
17. NCCN Clinical Practice Guidelines in OncologyTM. Kidney Cancer 2009; 2.
2. Матвеев Б.П., Матвеев В.Б., Волкова М.И. Онкоурология. 2008; 4.
3. Petrilak D et al. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin Am 1993; 29A: 997.
4. Savage PD. Renal cell cancer. Lippincott Co; 1995.
5. Strumberg D et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965–72.
6. Clark JW et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Clin Cancer Res 2005; 11: 5472–80.
7. Awada A et al. Phase I clinical and pharmacokinetic of BAY 43-9006 administered for 21 days on 7 days off in patients with advanced refractory solid tumors. Br J Cancer 2005; 92: 1855–61.
8. Amato R et al. Phase II trail of intra-patient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25: abstr 5026.
9. Szczylik C et al. Randomized phase II trail of first-line treatment with sorafenib vs interferon in patients with advanced renal cell carcinoma. J ClinOncol 2007; 25: abstr 5025.
10. Ryan CW, Goldman BN et al. Sorafenib plus interferon-?2b as first-line therapy for advanced renal cell carcinoma: SWOG 0412. J Clin Oncol 2006; 24: abstr 4525.
11. Gollob J et al. Комбинация сорафениба и интерферона альфа-2b в 1–2 линиях терапии метастатического почечноклеточного рака: исследование II фазы. J Clin Oncol (русское издание). 2007; 1 (4).
12. Ratain MJ, Elsen T et al. Phase II placebo-controlled randomized discontination trail of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–12.
13. Escudier B, Szczylik C et al. Randomized phase III trail of the multikinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Eur J Canc 2005; 3: 226.
14. Escudier B, Eisen T et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 2007; 357: 203.
15. Bukowski R et al. Final results of the randomized phase III trail of sorafenib in advanced renal cell carcinoma. Survival and biomarker analisis. J Clin Oncol 2007; 25: abstr 5023.
16. Knox JJ, Figlin R et al. Inv Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded accsess trail in North America: Safety and efficacy. J Clin Oncol 2007; 25: abstr 5011.
17. NCCN Clinical Practice Guidelines in OncologyTM. Kidney Cancer 2009; 2.
Авторы
К.Э.Подрегульский
Кафедра онкологии ГОУ ДПО РМАПО, Москва
Кафедра онкологии ГОУ ДПО РМАПО, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.